Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Oosting

Showing results (151-160 of 156) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 156 results.
JAMA Dermatology|August 10, 2022
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay RegistryLotte S Spekhorst, Marlies de Graaf, Nicolaas P A Zuithoff, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 13, 2026
Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDayLian F van der Gang, Nicolaas P A Zuithoff, Inge M Haeck, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 3, 2025
Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay resultsLian F van der Gang, Keneshka Atash, Nicolaas P A Zuithoff, et al.
Journal of the American Academy of Dermatology|April 23, 2024
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registryJunfen Zhang, Celeste M Boesjes, Laura Loman, et al.
Allergy|December 9, 2025
Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay RegistryLian F van der Gang, Celeste M Boesjes, Nicolaas P A Zuithoff, et al.
JAMA Dermatology|August 7, 2024
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic DermatitisCeleste M Boesjes, Esmé Kamphuis, Marlies de Graaf, et al.
Pageof 16

Showing results (151-160 of 156) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 156 results.
JAMA Dermatology|August 10, 2022
Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay RegistryLotte S Spekhorst, Marlies de Graaf, Nicolaas P A Zuithoff, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 13, 2026
Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDayLian F van der Gang, Nicolaas P A Zuithoff, Inge M Haeck, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 3, 2025
Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay resultsLian F van der Gang, Keneshka Atash, Nicolaas P A Zuithoff, et al.
Journal of the American Academy of Dermatology|April 23, 2024
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registryJunfen Zhang, Celeste M Boesjes, Laura Loman, et al.
Allergy|December 9, 2025
Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay RegistryLian F van der Gang, Celeste M Boesjes, Nicolaas P A Zuithoff, et al.
JAMA Dermatology|August 7, 2024
Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic DermatitisCeleste M Boesjes, Esmé Kamphuis, Marlies de Graaf, et al.
Pageof 16